Atlas Trials

CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer

Clinical trial NCT01871480 · TERMINATED

Trial details

NCT number
NCT01871480
Sponsor
Kunming Medical University
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2013-05-01
Primary completion
2015-11-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.